Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis

Código QR

Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis

Ami Vyas,1 Meghan Gabriel,2 Sobha Kurian3 1Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA; 2Pharmacy Quality Alliance, Alexandria, VA, USA; 3West Virginia University, School of Medicine, Morgantown, WV, USACorrespondence: Ami VyasDepartment of Pha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vyas A, Gabriel M, Kurian S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	guideline-concordant treatment decomposition her2-negative breast cancer seer-medicare database Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3dd7f9389d584259b1f2f2367ba707ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Impact of Marital Status on Survival in Patients with Ocular and Periocular Malignancies: A Retrospective Analysis of 3159 Patients from the SEER Database
por: Loya A, et al.
Publicado: (2020)

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
por: Lin X, et al.
Publicado: (2021)

Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
por: Xiaoshuang Lyu, et al.
Publicado: (2021)

Unicompartmental knee arthroplasty: A PearlDiver study evaluating complications rates, opioid use and utilization in the Medicare population
por: Brandon L. Morris, et al.
Publicado: (2021)

Conditional Survival of Advanced Epithelial Ovarian Cancer: A Real-World Data Retrospective Cohort Study From the SEER Database
por: Peng Zheng, et al.
Publicado: (2021)

Redundancy in ELF: A Corpus-Based Study on Negative and Modal Concord
por: Dorota Watkowska
Publicado: (2021)

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
por: Editorial Board
Publicado: (2021)

Impact of hospital and sociodemographic factors on utilization of drug-eluting stents in 2011-2012 Medicare cohort
por: Tushar A Tuliani, et al.
Publicado: (2017)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Diana B. Peckys, et al.
Publicado: (2021)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Mohammed Safi, et al.
Publicado: (2021)

Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
por: Lei Lei, et al.
Publicado: (2021)

Nomogram to Predict the Occurrence and Prognosis of Distant Metastasis in T1N0 Colon Cancer: A SEER Data-Based Study
por: Liu Y, et al.
Publicado: (2021)

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods
por: Saglican,Yesim, et al.
Publicado: (2015)

PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
por: Editorial Board
Publicado: (2021)

Avatime noun classes and concord
por: Russell G. Schuh
Publicado: (1995)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

Primary neuroendocrine tumors of the ovary: Management and outcomes
por: Li Pang, et al.
Publicado: (2021)

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
por: Benedikt Hoeh, et al.
Publicado: (2021)

Risk Assessment of Pulmonary Metastasis for Cervical Cancer Patients by Ensemble Learning Models: A Large Population Based Real-World Study
por: Zhu M, et al.
Publicado: (2021)

Study on concordance of specific cytological diagnosis with histology in a teaching hospital
por: Akinfenwa Taoheed Atanda, et al.
Publicado: (2021)

The noun classes and concord of Congo Copperbelt Swahili
por: Nkulu Kabuya
Publicado: (1999)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
por: Li J, et al.
Publicado: (2017)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
por: Chao Li, et al.
Publicado: (2021)

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
por: Lower EE, et al.
Publicado: (2017)

The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
por: Ilana Schlam, et al.
Publicado: (2021)

Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER
por: Li Y, et al.
Publicado: (2021)

The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma
por: Xiaodi Zhang, et al.
Publicado: (2021)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
por: Yalikong A, et al.
Publicado: (2021)

EXTRACCIÓN DE PECTINAS DE VITIS LABRUSCA CV. CONCORD PARA PRODUCIR JALEAS
por: Fredes Monsalves,Claudio, et al.
Publicado: (2009)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)

Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
por: Editorial Board
Publicado: (2021)

Concordance in mSEGA Tool to Frailty Diagnosis between Medical Doctors and Nurses
por: Abrar-Ahmad Zulfiqar, et al.
Publicado: (2021)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub NM, et al.
Publicado: (2019)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan AS, et al.
Publicado: (2021)

Analysis of the feasibility of microwave ablation for colorectal liver metastases: a preliminary report
por: Yiren Hu, et al.
Publicado: (2019)

Construction and Validation of Two Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of NSCLC Patients with Bone Metastasis
por: Dong Q, et al.
Publicado: (2021)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021)

Down-Regulation of USP8 Suppresses HER-3 Positive Gastric Cancer Cells Proliferation [Corrigendum]
por: Sun J, et al.
Publicado: (2021)

Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
por: Serafin Morales, et al.
Publicado: (2021)